Maravai Lifesciences Financials
MRVI Stock | USD 2.30 0.06 2.68% |
Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
---|---|---|---|---|---|---|---|---|---|
Debt Equity Ratio | 0.11 | 0.1148 |
|
| |||||
Current Ratio | 4.26 | 7.5327 |
|
|
The financial analysis of Maravai Lifesciences is a critical element in measuring its lifeblood. Investors should not minimize Maravai Lifesciences' ability to pay suppliers or employees on time, ensuring interest payments are not accumulating.
Net Income |
|
Maravai | Select Account or Indicator |
Maravai Lifesciences Holdings Earnings Geography
Maravai Lifesciences Stock Summary
Maravai Lifesciences competes with Roivant Sciences, Krystal Biotech, Akero Therapeutics, Apellis Pharmaceuticals, and Halozyme Therapeutics. Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases in the United States and internationally. Maravai LifeSciences Holdings, Inc. was incorporated in 2020 and is headquartered in San Diego, California. Maravai LifeSciences operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 470 people.Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
Instrument | USA Stock View All |
Exchange | NASDAQ Exchange |
ISIN | US56600D1072 |
CUSIP | 56600D107 |
Location | California; U.S.A |
Business Address | 10770 Wateridge Circle, |
Sector | Life Sciences Tools & Services |
Industry | Health Care |
Benchmark | Dow Jones Industrial |
Website | www.maravai.com |
Phone | 858 546 0004 |
Currency | USD - US Dollar |
Maravai Lifesciences Key Financial Ratios
Return On Equity | -0.38 | ||||
Profit Margin | (0.56) % | ||||
Operating Margin | (0.48) % | ||||
Price To Sales | 2.20 X | ||||
Revenue | 259.19 M |
Maravai Lifesciences Key Balance Sheet Accounts
2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
Total Assets | 1.3B | 1.9B | 2.3B | 1.5B | 1.0B | 1.4B | |
Other Current Liab | 40.8M | 64.3M | 88.3M | 59.5M | 36.4M | 52.9M | |
Other Liab | 15.9M | 400.4M | 713.6M | 693.4M | 797.4M | 405.2M | |
Net Tangible Assets | (280.7M) | (313.4M) | 315.5M | 44.9M | 51.6M | 54.2M | |
Net Debt | 354.6M | (17.0M) | (46.9M) | 36.0M | (285.1M) | (270.8M) | |
Retained Earnings | 854K | 184.6M | 404.8M | 285.7M | 140.9M | 147.1M | |
Accounts Payable | 3.0M | 8.2M | 6.0M | 10.7M | 12.0M | 8.0M | |
Cash | 236.2M | 551.3M | 632.1M | 575.0M | 322.4M | 371.4M | |
Other Assets | 805K | 435.9M | 812.5M | 806.1M | 927.0M | 973.4M | |
Long Term Debt | 528.6M | 524.6M | 522.0M | 518.7M | 290.5M | 480.0M | |
Net Receivables | 51.0M | 117.5M | 146.8M | 55.7M | 38.5M | 69.7M | |
Inventory | 33.3M | 51.6M | 43.2M | 51.4M | 50.1M | 40.5M | |
Other Current Assets | 11.1M | 19.7M | 25.8M | 17.8M | 18.1M | 15.4M | |
Total Liab | 1.1B | 1.4B | 1.4B | 697.6M | 431.0M | 409.5M | |
Net Invested Capital | 623.1M | 846.1M | 1.1B | 940.9M | 621.2M | 795.9M | |
Total Current Assets | 331.6M | 740.0M | 847.9M | 699.9M | 429.1M | 497.0M | |
Capital Stock | 2.6M | 2.6M | 2.6M | 2.5M | 2.5M | 2.4M | |
Net Working Capital | 200.8M | 646.3M | 737.8M | 612.4M | 372.2M | 411.5M | |
Short Term Debt | 10.6M | 9.7M | 11.7M | 12.9M | 5.4M | 8.7M | |
Intangible Assets | 177.7M | 117.6M | 216.7M | 221.0M | 195.0M | 211.2M | |
Common Stock | 2.6M | 2.6M | 2.6M | 2.5M | 2.5M | 2.4M |
Maravai Lifesciences Key Income Statement Accounts
2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
Tax Provision | 2.9M | 61.5M | 60.8M | (1.6M) | (1.9M) | (1.8M) | |
Net Interest Income | (30.7M) | (30.3M) | (18.1M) | (18.1M) | (20.3M) | (21.3M) | |
Interest Expense | 30.7M | 30.3M | 20.4M | 45.9M | 47.7M | 36.5M | |
Total Revenue | 284.1M | 799.2M | 883.0M | 288.9M | 259.2M | 437.1M | |
Gross Profit | 204.4M | 658.7M | 714.0M | 140.2M | 108.3M | 102.9M | |
Operating Income | 67.6M | 554.6M | 574.2M | (31.6M) | (235.6M) | (223.8M) | |
Ebit | 112.4M | 561.0M | 571.9M | 663.6M | (213.8M) | (203.1M) | |
Research Development | 9.3M | 15.2M | 18.4M | 17.3M | 19.2M | 13.8M | |
Ebitda | 138.3M | 585.8M | 610.0M | 712.4M | (156.9M) | (149.1M) | |
Cost Of Revenue | 79.6M | 140.6M | 169.0M | 148.7M | 150.9M | 128.3M | |
Income Before Tax | 81.7M | 530.8M | 551.5M | 617.7M | (261.5M) | (248.4M) | |
Net Income | 76.9M | 469.3M | 490.7M | (119.0M) | (144.8M) | (137.6M) | |
Income Tax Expense | 2.9M | 61.5M | 60.8M | 756.1M | (1.9M) | (1.8M) | |
Minority Interest | 66.2M | (287.2M) | (270.5M) | (34.5M) | 114.8M | 120.5M |
Maravai Lifesciences Key Cash Accounts
2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
Change To Inventory | (19.1M) | (21.6M) | 9.5M | 649K | 377K | 395.9K | |
Investments | 6.1M | 105.7M | (267.6M) | (127.9M) | (24.3M) | (25.5M) | |
Change In Cash | 211.5M | 315.1M | 80.9M | (57.2M) | (252.6M) | (239.9M) | |
Net Borrowings | (2.6M) | 196.9M | (6M) | (5.4M) | (4.9M) | (4.7M) | |
Free Cash Flow | 126.8M | 353.7M | 518.9M | 60.7M | (22.2M) | (21.1M) | |
Depreciation | 25.8M | 24.8M | 38.1M | 48.8M | 48.4M | 36.5M | |
Other Non Cash Items | (7.5M) | (6.2M) | (8.7M) | (690.9M) | 169.3M | 177.7M | |
Capital Expenditures | 25.4M | 14.9M | 17.1M | 65.6M | 29.7M | 27.2M | |
Net Income | 78.8M | 469.3M | 490.7M | (119.0M) | (259.6M) | (246.6M) | |
End Period Cash Flow | 236.2M | 551.3M | 632.1M | 575.0M | 322.4M | 371.4M | |
Change To Netincome | 477K | (340K) | 45.8M | 320.0M | 368.0M | 386.4M |
Maravai Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Maravai Lifesciences's current stock value. Our valuation model uses many indicators to compare Maravai Lifesciences value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Maravai Lifesciences competition to find correlations between indicators driving Maravai Lifesciences's intrinsic value. More Info.Maravai Lifesciences Holdings is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . As of now, Maravai Lifesciences' Return On Equity is increasing as compared to previous years. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Maravai Lifesciences' earnings, one of the primary drivers of an investment's value.Maravai Lifesciences' Earnings Breakdown by Geography
Maravai Lifesciences Systematic Risk
Maravai Lifesciences' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Maravai Lifesciences volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was twenty with a total number of output elements of fourty-one. The Beta measures systematic risk based on how returns on Maravai Lifesciences correlated with the market. If Beta is less than 0 Maravai Lifesciences generally moves in the opposite direction as compared to the market. If Maravai Lifesciences Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Maravai Lifesciences is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Maravai Lifesciences is generally in the same direction as the market. If Beta > 1 Maravai Lifesciences moves generally in the same direction as, but more than the movement of the benchmark.
Maravai Lifesciences Thematic Clasifications
Maravai Lifesciences Holdings is part of Pharmaceutical Products investing theme. If you are a theme-oriented, socially responsible, and at the same time, a result-driven investor, you can align your investing habits with your values without jeopardizing your expectations about returns. You can easily create an optimal portfolio of stocks, ETFs, funds, or cryptocurrencies based on a specific theme of your liking. USA Equities from Pharmaceutical Products industry as classified by Fama & French. Fama and French investing themes focus on testing asset pricing under different economic assumptions
This theme covers USA Equities from Pharmaceutical Products industry as classified by Fama & French. Fama and French investing themes focus on testing asset pricing under different economic assumptions. Get More Thematic Ideas
Pharmaceutical Products | View |
Today, most investors in Maravai Lifesciences Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Maravai Lifesciences' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Maravai Lifesciences growth as a starting point in their analysis.
Price Earnings To Growth Ratio |
|
Maravai Lifesciences March 26, 2025 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Maravai Lifesciences help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Maravai Lifesciences Holdings. We use our internally-developed statistical techniques to arrive at the intrinsic value of Maravai Lifesciences Holdings based on widely used predictive technical indicators. In general, we focus on analyzing Maravai Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Maravai Lifesciences's daily price indicators and compare them against related drivers.
Information Ratio | (0.23) | |||
Maximum Drawdown | 31.34 | |||
Value At Risk | (7.91) | |||
Potential Upside | 5.83 |
Complementary Tools for Maravai Stock analysis
When running Maravai Lifesciences' price analysis, check to measure Maravai Lifesciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Maravai Lifesciences is operating at the current time. Most of Maravai Lifesciences' value examination focuses on studying past and present price action to predict the probability of Maravai Lifesciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Maravai Lifesciences' price. Additionally, you may evaluate how the addition of Maravai Lifesciences to your portfolios can decrease your overall portfolio volatility.
Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
Commodity Directory Find actively traded commodities issued by global exchanges | |
Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios |